Tiny sigma-tau adds 22 new employees to sales force
The 12-person sales team of sigma-tau Pharmaceuticals Inc., Gaithersburg, MD, added 22 new employees to its force.
The 12-person sales team of sigma-tau Pharmaceuticals Inc., Gaithersburg, MD, added 22 new employees to its force.
The small company, the U.S. subsidiary of Italy's largest pharmaceutical company sigma-tau S.p.A, markets Carnitor® (levocarnitine) for the treatment of carnitine deficiency.
"Our company started in 1989 to market Carnitor in the United States," said Brad Stewart, the company's manager of marketing. "We started with six people and then went to 12 in 1996. Now we've gone to 30 reps."
How does a size increase that may seem insignificant to some companies affect one as intimate as sigma-tau?
"When we added six, it was such a small number that it was still like a close-knit family," Stewart said. "Twenty-two was a bigger jump."
The company has added an additional regional manager to its existing two and is in the process of hiring a full-time sales trainer. The new sales representatives are learning their new territories by shadowing the representatives who covered them before. By early 1998, the new representatives will assume full responsibility for their customers.
"This makes things much easier for the people who were already with us," Stewart said. "We had people covering five or six states. Before, the smallest territory was three states, now it's half the Los Angeles area. This gives them more time to spend with their customers, less time to travel and [the chance to] see their customers more frequently. To us, it's a pretty dramatic difference." PR
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
